In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents: a report from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry.
暂无分享,去创建一个
M. Pencina | N. Kleiman | D. Cohen | D. Moliterno | D. Cutlip | J. Saucedo | John J. Lopez | F. Latif | D. Nassif | Chen-Hsing Yen | J. Lopez | John J. Lopez | D. Cohen
[1] J. Granada,et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. , 2007, JAMA.
[2] G. Nakazawa,et al. Impact of renal insufficiency on clinical and angiographic outcomes following percutaneous coronary intervention with sirolimus‐eluting stents , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[3] K. Alexander,et al. Sex Differences in Major Bleeding With Glycoprotein IIb/IIIa Inhibitors: Results From the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines) Initiative , 2006, Circulation.
[4] A. Garg,et al. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. , 2006, JAMA.
[5] S. Steinhubl,et al. Impact of drug-eluting stents on outcomes of patients with end-stage renal disease undergoing percutaneous coronary revascularization. , 2006, The Journal of invasive cardiology.
[6] Qi Zhang,et al. Long term clinical outcomes in patients with moderate renal insufficiency undergoing stent based percutaneous coronary intervention. , 2006, Chinese medical journal.
[7] K. Alexander,et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. , 2005, JAMA.
[8] G. Stone,et al. Impact of moderate renal insufficiency on restenosis and adverse clinical events after paclitaxel-eluting and bare metal stent implantation: results from the TAXUS-IV Trial. , 2005, American heart journal.
[9] J. Yee,et al. Risk of bleeding and restenosis among chronic kidney disease patients undergoing percutaneous coronary intervention. , 2005, Clinical nephrology.
[10] David J Cohen,et al. Design of a registry to characterize "real-world" outcomes of percutaneous coronary revascularization in the drug-eluting stent era. , 2005, American heart journal.
[11] James J. Gugger,et al. Percutaneous Coronary Intervention–Related Bleeding Risk Factors in Current Practice , 2005, The Annals of pharmacotherapy.
[12] E. Topol,et al. The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial. , 2005, American heart journal.
[13] P. Serruys,et al. Impact of baseline renal function on mortality after percutaneous coronary intervention with sirolimus-eluting stents or bare metal stents. , 2005, The American journal of cardiology.
[14] J. J. Griffin,et al. Impact of Renal Insufficiency in Patients Undergoing Primary Angioplasty for Acute Myocardial Infarction , 2003, Circulation.
[15] R. Califf,et al. Anticoagulation in acute cardiac care in patients with chronic kidney disease. , 2003, American heart journal.
[16] M. Bell,et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. , 2002, Journal of the American College of Cardiology.
[17] David O. Williams,et al. ACC/AHA Guidelines for Percutaneous Coronary Intervention (Revision of the 1993 PTCA Guidelines)—Executive Summary , 2001 .
[18] K A Eagle,et al. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines)--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coro , 2001, Journal of the American College of Cardiology.
[19] A. Levin,et al. Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[20] I. Palacios,et al. Are Patients With Renal Failure Good Candidates for Percutaneous Coronary Revascularization in the New Device Era? , 2000, Circulation.
[21] S. Hosoda,et al. Comparison of clinical outcomes of coronary artery bypass grafting and percutaneous transluminal coronary angioplasty in renal dialysis patients. , 1996, The Annals of thoracic surgery.
[22] K. Mann,et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. , 1991, Annals of internal medicine.
[23] A. Schwartz,et al. Selective Reduction of Serotonin Storage and ATP Release in Chronic Renal Failure Patient Platelets , 1990, American journal of hematology.
[24] B. Rutherford,et al. Short- and long-term outcome of percutaneous transluminal coronary angioplasty in chronic dialysis patients. , 1990, American heart journal.
[25] B. Gersh. Incidence, Predictors, and Outcome of Thrombosis After Successful Implantation of Drug-Eluting Stents , 2006 .
[26] G. Eknoyan,et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[27] J. Ioannidis,et al. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. , 2003, Journal of the American College of Cardiology.
[28] Cockcroft Dw,et al. Prediction of Creatinine Clearance from Serum Creatinine , 1976 .